Literature DB >> 14000759

Treatment of leukaemias and reticuloses with uracil mustard.

J F WILKINSON, M S BOURNE, M C ISRAELS.   

Abstract

Entities:  

Keywords:  CARCINOMA, BRONCHOGENIC; HODGKIN'S DISEASE; LEUKEMIA, LYMPHOCYTIC; LEUKEMIA, MYELOCYTIC; LYMPHOMA; LYMPHOMA, GIANT FOLLICULAR; NITROGEN MUSTARD COMPOUNDS; POLYCYTHEMIA VERA; SARCOMA, RETICULUM CELL

Mesh：

Substances：

Year:  1963        PMID： 14000759      PMCID： PMC2124314          DOI： 10.1136/bmj.1.5345.1563

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  7 in total

1.  Clinical observations on newer chemotherapeutic agents.

Authors:  C L SPURR; D M HAYES
Journal:  South Med J       Date:  1960-08       Impact factor: 0.954

2.  Chemotherapy of advanced ovarian cancer.

Authors:  V K VAITKEVICIUS; R W TALLEY; M J BRENNAN; J E KELLY
Journal:  J Mich State Med Soc       Date:  1961-04

3.  Therapeutic spectrum of uracil-mustard, a new oral antitumor drug. With special reference to the effects of small dosage in lymphomas, chronic leukemias, and ovarian carcinoma.

Authors:  E SHANBROM; S MILLER; H HAAR; R OPFELL
Journal:  JAMA       Date:  1960-11-26       Impact factor: 56.272

4.  Uracil mustard, a new alkylating agent for oral administration in the management of patients with leukemia and lymphoma.

Authors:  B J KENNEDY; A THEOLOGIDES
Journal:  N Engl J Med       Date:  1961-04-20       Impact factor: 91.245

5.  Antitumor activity of 5-bis(2-chloroethyl) amino uracil against sarcoma 180 and Ehrlich carcinoma.

Authors:  J S EVANS; G D MENGEL
Journal:  Proc Soc Exp Biol Med       Date:  1958-12

6.  Uracil mustard therapy in acute leukemia in children.

Authors:  F S PORTER; J HOLOWACH; W G THURMAN
Journal:  Cancer Chemother Rep       Date:  1962-05

7.  Treatment of Hodgkin's granuloma, chronic lymphatic leukaemia, polycythaemia vera, and other reticuloses with triethylenethiophosphoramide.

Authors:  M C ISRAELS; B J LEONARD; J F WILKINSON
Journal:  Lancet       Date:  1956-11-17       Impact factor: 79.321
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.